A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis Clinical Trial

Official title:

A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02871401
• Other study ID #: 160693
• Status: Completed
• Phase: Phase 1
• Start date: January 3, 2018
• Est. completion date: January 31, 2020

Study information

• Verified date: April 2022
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators will conduct a single-center, prospective, randomized, placebo-controlled, double-blind pilot study of anti-herpesvirus therapy in patients with idiopathic pulmonary fibrosis (IPF). Patients with mild, moderate or severe IPF with serologic evidence of current or past Epstein-Barr Virus (EBV) or cytomegalovirus (CMV) infection. Randomization will be to pirfenidone plus placebo or pirfenidone plus valganciclovir. Thirty subjects will be enrolled and randomized to treatment with pirfenidone plus valganciclovir (20 subjects) or pirfenidone plus placebo (10 subjects) for 12 weeks. The primary outcome will be safety and tolerability will be determined by type, frequency and duration of adverse events (AEs) and serious adverse events (SAEs) after 12 weeks of study drug treatment. All study subjects will be offered bronchoscopy with bronchoalveolar lavage (BAL) at study initiation and upon completion of treatment (12 weeks). Subjects will then be followed up at routine clinic visits at 6, 9 and 12 months for data collection.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: January 31, 2020
• Est. primary completion date: January 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 80 Years

Eligibility

Inclusion Criteria:

1. age >21 and <80 years

2. ability to provided informed consent

3. diagnosis of probable or definite IPF according to American Thoracic Society (ATS) criteria

4. tolerance of full-dose (2403 mg/day) pirfenidone

5. Positive serology for EBV or CMV

Exclusion Criteria:

1. FVC < 40% predicted

2. Diffusing capacity for carbon monoxide (DLCO) < 35% predicted (Crapo)

3. Forced expiratory volume (FEV)1/FVC <0.7

4. Significant centrilobular emphysema (>40% by HRCT)

5. Active tobacco use (cigarette or cigar smoking)

6. Resting oxygen saturation (SpO2) on room air <89%

7. Listed for lung transplantation defined as being assigned a lung allocation score

8. environmental exposure (occupational, environmental, drug, etc.) felt by the principal investigator (PI) to be the etiology of the interstitial disease

9. diagnosis of collagen-vascular conditions (according to the published American College of Rheumatology criteria)

10. history of unstable or deteriorating cardiac disease

11. acute coronary syndrome, coronary artery bypass, or angioplasty within 3 months of screening

12. uncontrolled arrhythmia

13. uncontrolled hypertension

14. known HIV or hepatitis C

15. known cirrhosis or chronic active hepatitis

16. active substance or alcohol abuse

17. pregnancy or lactation

18. Women of childbearing potential who are not using a medically approved means of contraception. Subjects will be considered of childbearing potential if they are not surgically sterile or have not been postmenopausal for at least 2 years [any subject who is postmenopausal for < 2 years will be required to have a follicle-stimulating hormone (FSH) level to assess her potential to become pregnant

19. clinically relevant lab abnormalities (obtained within 30 days before enrollment),

including:

1. creatinine > 2 x upper limit of normal (ULN)

2. hematology outside of specified limits: white blood cells (WBCs) < 3,500/mm3; hematocrit < 25% or > 59%; platelets < 100,000/mm3;

3. total bilirubin > 2 x ULN

4. Aspartate (AST) or alanine aminotransferases (ALT)/ serum glutamic-oxaloacetic; transaminase (SGOT), or serum glutamic pyruvic transaminase (SGPT) > 2.0 x ULN

5. alkaline phosphatase > 3 x ULN

6. albumin < 3.0 mg/dL at screening

20. known hypersensitivity to study medication

21. any condition that, in the judgment of the PI, might cause participation in this study to be detrimental to the subject or that the PI deems makes the subject a poor candidate

22. any therapy with immunosuppressants such as prednisone, azathioprine, or mycophenolate currently or anticipated to be needed during the study period (subjects on these drugs prior to the study will require a 30-day washout period before randomization)

23. participation in another IPF clinical treatment trial during the study period (if completing another IPF clinical treatment trial, then a 30-day washout period is required before randomization)

24. requirement for chronic suppressive therapy with valacyclovir for recurrent herpes virus infection

25. History of myelodysplasia, aplastic anemia, refractory anemia, or multiple myeloma.

Related Conditions & MeSH terms

• Fibrosis
• Idiopathic Pulmonary Fibrosis
• Pulmonary Fibrosis

Intervention

Drug:
• Valganciclovir
Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
• Placebo
Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center	Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in Forced Vital Capacity (FVC)	Change in FVC percent predicted compared to baseline	Baseline vs. 12 weeks, 1 year
Primary	Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events	Proportion of study subjects who discontinue study drug due to adverse events	12 weeks
Secondary	Adverse Events - Number	Number of subjects with each reported adverse event	12 weeks
Secondary	Serious Adverse Events	Number of subjects with each serious adverse event	12 weeks
Secondary	Total # Adverse Events	Total number of adverse events	Randomization to 16 weeks